4.5 Review

TGF-β in renal fibrosis: triumphs and challenges

期刊

FUTURE MEDICINAL CHEMISTRY
卷 12, 期 9, 页码 853-866

出版社

FUTURE SCI LTD
DOI: 10.4155/fmc-2020-0005

关键词

immune cells; inflammation; renal fibrosis; TGF-beta; therapy

资金

  1. Research Grants Council of Hong Kong [GRF 14121816, 14163317, 14117418, 14104019, R4012-18F, C7018-16G]
  2. Lui Che Woo Institute of Innovative Medicine (CARE)
  3. Health and Medical Research Fund of Hong Kong [HMRF 0314048, 05161326, 06173986, 14152321]
  4. Science and Technology Planning Project of Guangdong Province [2017B030314166]
  5. National Natural Science Foundation of China [81873261, 81903956]
  6. Project of Guangdong Province Administration of Traditional Chinese Medicine [20201133]
  7. Guangdong-Hong KongMacao-Joint Labs Program from Guangdong Science and Technology Department [2019B121205005]

向作者/读者索取更多资源

Renal fibrosis is a hallmark of chronic kidney disease. Although considerable achievements in the pathogenesis of renal fibrosis have been made, the underlying mechanisms of renal fibrosis remain largely to be explored. Now we have reached the consensus that TGF-beta is a master regulator of renal fibrosis. Indeed, TGF-beta regulates renal fibrosis via both canonical and noncanonical TGF-beta signaling. Moreover, ongoing renal inflammation promotes fibrosis as inflammatory cells such as macrophages, conventional T cells and mucosal-associated invariant T cells may directly or indirectly contribute to renal fibrosis, which is also tightly regulated by TGF-beta. However, anti-TGF-beta treatment for renal fibrosis remains ineffective and nonspecific. Thus, research into mechanisms and treatment of renal fibrosis remains highly challenging.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据